Seeking Alpha

Henry McCusker's  Instablog

Henry McCusker
Send Message
Editor and Publisher ... Henry enters his twelve (12) year at RegMed Investors which aggregates, curates and creates bottom-line content of regenerative medicine and cell therapy news providing a "vetted" selection of relevant and high-impact synthesis. He was VP - Strategic Planning... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
View Henry McCusker's Instablogs on:
  • Cytori (CYTX) Patent In Australia

    Cytori (NASDAQ:CYTX) Patent in Australia

    CYTX has received a patent covering methods of treating cardiovascular disease using adipose-derived regenerative cells (ADRCs) from the Australian Therapeutic Goods Administration (NASDAQ:TGA) with the Celution® System being approved for commercial use through inclusion on the TGA for autologous re-implantation and re-infusion of a patient's own ADRCs

    The patent covers the therapeutic use of ADRCs for improving cardiac function and mechanics by preventing the deleterious histopathological and structural changes that occur in the heart following a heart attack (cardiac remodeling).

    The patent is not limited to any particular way of obtaining ADRCs, covering both manual and automated methods of obtaining the cells. This includes the use of a sterile, closed system such as the proprietary Celution® System. The claims also cover multiple cell populations and cell delivery methods, including intravenous delivery.

    The Bottom Line: This approval enables physicians to treat critical unmet medical needs with point-of-care cell therapies and to conduct important clinical research in promising therapeutic areas. The patent complements Cytori's existing patents in Australia covering the Celution® System.

    CYTX closed at $2.16, with a winnowing version of its past share price <consider it was trading at $2.81 on 8/1/13 and $2.80 on 1/2/13 versus $2.14 on 5/21/12. Where the next version of … testosterone as the cash position is dwindles with a 52 week change of -49.41% and the 52 week low was $2.09? Volume has hugged the low end of the 3 month metric noticing the only big day of 1.1 M on 9/20/13. A … HOLD until some granular news is evident.

    Where's the meat?

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Oct 10 6:14 PM | Link | Comment!
  • Aastrom (ASTM) 1 For 20 Reverse Stock Split -“Staying Alive” Is More Than A Song

    ASTM's BOD <after a shareholder vote>has approved a 1 for 20 reverse stock split of the common stock effective on 10/16/13. Following the reverse stock split, the company expects to have approximately 4.4 M shares of common stock outstanding.

    The reverse stock split is intended to increase the per share trading price of ASTM's stock to satisfy the $1.00 minimum bid price requirement for continued listing on NASDAQ The number of authorized but unissued shares of the company's common stock will be proportionally reduced.

    No fractional shares of common stock will be issued as a result of the reverse stock split and shareholders of record will receive cash in lieu of fractional shares to which they would otherwise be entitled, based upon the closing price of the stock on 10/15/13.

    The Bottom Line: I take it my mid-day <opinion> comments of a 1 for 20 reverse and lack of communication negligence cut to the heart of … fiduciary responsibility of Aastrom (NASDAQ:ASTM) lawyer CEO … www.scimitarequity.com/articles/musical-... … with the press release of the reverse split. Where is the … rest of the SEC FILING?

    A vote approved an amendment to the Restated Articles of Incorporation, to increase the number of shares of the common stock authorized for issuance thereunder from 150,000,000 shares to 300,000,000 shares.

    No fractional shares will be issued, and in lieu thereof, any person who would otherwise be entitled to a fractional share as a result of the Reverse Stock Split will be entitled to receive a cash payment equal to the fraction to which such holder would otherwise be entitled multiplied by the closing price of a share of Common Stock on The NASDAQ Capital Market on October 15, 2013 - paying out CASH from the paltry offering and expensive executive salaries.

    So … are they or aren't they changing … to a different fiscal year <to eschew results for comparable metrics>?

    The reverse is a GOD's gift to short sellers as the 2.08 M <3.20%> shares are short of the float of 29.76 M shares.

    ASTM closed at $0.23 UP +$0.01 and then dropped in the after-market -$0.04 <-18.8%> to a whopping $0.19. See you at $0.15 and a 1 for 20 reverse with a soon needed financing.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Oct 10 6:09 PM | Link | Comment!
  • Cytori (CYTX) Obtains Celution® System Approval In Singapore

    The Celution® System enables access to a patient's own ADRCs at the point-of-care for a range of injuries and conditions.

    CYTX has received approval from the Health Sciences Authority (NYSE:HSA) in Singapore for the Celution® System for autologous re-implantation or re-infusion of a patient's own adipose-derived regenerative cells (ADRCs).

    The Bottom Line: The approval and claims in Singapore strengthens market access in the region and reinforcing CYTX's global regulatory strategy. Anticipate a relevant impact on sales in 2014 combined with recent approvals and registrations in Australia, New Zealand and in Japan. Asia-Pacific has been and continues to be a key region for CYTX related to the use of ADRCs to restore blood flow.

    CYTX closed Friday <10/4> at $2.26 having experienced at a tough week + of depreciating share pricing. This news should cause some movement as there hasn't been much to … speculate the visibility and "share pricing". This market has not been good to the RegMed sector but, I see better horizons for CYTX and this is just one element to the long-term revenue guidance. The key is still … the progress of the ATHENA trial and BARDA contract.

    Add $0.10 to $0.20 to the share pricing over the week, understanding the issues of government budget issues off-setting visibility to the sector. A … BUY.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Oct 07 9:28 AM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.